$0.45 EPS Expected for Itron, Inc. (ITRI) This Quarter

Brokerages expect that Itron, Inc. (NASDAQ:ITRI) will post earnings per share of $0.45 for the current quarter, according to Zacks. Two analysts have made estimates for Itron’s earnings, with estimates ranging from $0.33 to $0.52. Itron posted earnings of $0.13 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 246.2%. The firm is scheduled to announce its next earnings results on Monday, May 13th.

On average, analysts expect that Itron will report full year earnings of $2.49 per share for the current year, with EPS estimates ranging from $2.44 to $2.54. For the next fiscal year, analysts expect that the company will post earnings of $3.53 per share, with EPS estimates ranging from $3.31 to $3.75. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Itron.

Itron (NASDAQ:ITRI) last released its quarterly earnings results on Wednesday, February 27th. The scientific and technical instruments company reported $0.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.20. Itron had a positive return on equity of 14.92% and a negative net margin of 4.18%. The business had revenue of $587.00 million during the quarter, compared to analysts’ expectations of $600.73 million. During the same period in the previous year, the business posted $1.01 earnings per share. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year.

A number of research firms recently issued reports on ITRI. JMP Securities cut their price target on Itron from $80.00 to $72.00 and set a “market outperform” rating for the company in a report on Thursday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $70.00 price target on shares of Itron in a report on Thursday, February 28th. BidaskClub raised Itron from a “sell” rating to a “hold” rating in a report on Saturday, February 23rd. Zacks Investment Research raised Itron from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Finally, Guggenheim began coverage on Itron in a report on Monday, December 3rd. They issued a “buy” rating and a $70.00 price target for the company. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $72.00.

Itron stock opened at $46.65 on Wednesday. The company has a debt-to-equity ratio of 1.35, a current ratio of 1.37 and a quick ratio of 1.03. Itron has a 12-month low of $44.35 and a 12-month high of $72.20. The stock has a market capitalization of $1.85 billion, a P/E ratio of 17.51, a price-to-earnings-growth ratio of 0.75 and a beta of 1.34.

In related news, CEO Philip Mezey sold 22,645 shares of Itron stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $60.75, for a total value of $1,375,683.75. Following the completion of the sale, the chief executive officer now directly owns 87,077 shares in the company, valued at $5,289,927.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michel Cadieux sold 3,350 shares of Itron stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $60.75, for a total value of $203,512.50. Following the completion of the sale, the senior vice president now owns 41,479 shares of the company’s stock, valued at $2,519,849.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 312,955 shares of company stock valued at $15,855,909. Corporate insiders own 2.32% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Itron by 1.2% in the third quarter. BlackRock Inc. now owns 5,114,960 shares of the scientific and technical instruments company’s stock worth $328,380,000 after purchasing an additional 58,386 shares during the period. Vanguard Group Inc. increased its position in Itron by 2.2% in the third quarter. Vanguard Group Inc. now owns 3,407,421 shares of the scientific and technical instruments company’s stock worth $218,756,000 after purchasing an additional 73,730 shares during the period. Vanguard Group Inc increased its position in Itron by 2.2% in the third quarter. Vanguard Group Inc now owns 3,407,421 shares of the scientific and technical instruments company’s stock worth $218,756,000 after purchasing an additional 73,730 shares during the period. Impax Asset Management Group plc increased its position in Itron by 15.3% in the fourth quarter. Impax Asset Management Group plc now owns 2,514,162 shares of the scientific and technical instruments company’s stock worth $118,895,000 after purchasing an additional 333,843 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Itron by 2.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,026,449 shares of the scientific and technical instruments company’s stock worth $48,541,000 after purchasing an additional 26,319 shares during the period. Hedge funds and other institutional investors own 97.89% of the company’s stock.

Itron Company Profile

Itron, Inc, a technology and service company, provides end-to-end solutions that measures, manages, and analyzes energy and water use worldwide. The company operates through three segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment offers hardware products that are used for measurement, control, or sensing.

Further Reading: No Load Funds

Get a free copy of the Zacks research report on Itron (ITRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Itron (NASDAQ:ITRI)

Receive News & Ratings for Itron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Itron and related companies with MarketBeat.com's FREE daily email newsletter.